BJH - volume 8, issue Abstract Book BHS, february 2017
G. Di Prinzio , J. Devreux , S. Lefebvre , S. Bailly MD, G. Verstraete , A. Bourgois , C. Pedreira , J-P. Defour PhD, A. Camboni MD, PhD, A. Marchandise , T. Pieters , M-C. Vekemans MD
BJH - volume 8, issue Abstract Book BHS, february 2017
J. Devreux , G. Di Prinzio , S. Bailly MD, S. Lefebvre , G. Verstraete , K. van Renterghem , A. Charlot , P. Saussoy MD, PhD, J-P. Defour PhD, N. Straetmans MD, PhD, X. Poiré MD, L. Michaux MD, PhD, M-C. Vekemans MD, V. Havelange MD, PhD
BJH - volume 8, issue Abstract Book BHS, february 2017
S. Bailly MD, M-C. Vekemans MD, B. Chatelain PharmD, M. André MD, T. Vander Borght , L. D’Hondt , L. Faugeras , G. Verstraete , J. Devreux , G. Di Prinzio , S. Lefevre
BJH - volume 8, issue Abstract Book BHS, february 2017
G. Verstraete , S. Lefevre , S. Bailly MD, G. Di Prinzio , J. Devreux , J-P. Defour PhD, P. D’Abadie , P. Van Eeckhout , F. Kino , C. Goemare , N. Lepage , L. Michaux MD, PhD, V. Havelange MD, PhD, E. Van den Neste MD, PhD, C. Lambert MD, L. Knoops MD, PhD, M-C. Vekemans MD, X. Poiré MD
BJH - volume 7, issue 1, february 2016
M-C. Vekemans MD
Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic malignancies characterized by peripheral blood cytopenias, due to ineffective erythropoiesis and a risk for progression to acute myeloid leukemia (AML). Progress in this field aims to decrease the transfusion burden, delay progression to AML, improve the quality-of-life of patients and extend survival.
(BELG J HEMATOL 2016; 7(1): 20–4)
Read moreBJH - volume 7, issue Abstract Book BHS, january 2016
N. Grailet , C. Ninane , N. Van Langendonck , C. Hermans MD, PhD, D. Latinne , L. Michaux MD, PhD, M-C. Vekemans MD
BJH - volume 7, issue Abstract Book BHS, january 2016
S. Amat , T. Tamakloe , N. Meité , V. Havelange MD, PhD, M-C. Vekemans MD, C. Lambert MD, E. Van den Neste MD, PhD, X. Poiré MD
Top
